Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. METHODS: In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes. Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks. The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point). RESULTS: A total of 272 participants underwent randomization. At baseline, the mean body weight was 108.7 kg, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 37.9. At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group. At week 36, the mean change ranged from -9.4% to -14.7% with orforglipron and was -2.3% with placebo. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo. The use of orforglipron led to improvement in all prespecified weight-related and cardiometabolic measures. The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts. The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class. CONCLUSIONS: Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“Between 65% and 96% of participants taking orforglipron achieved an A1C level below 7.0% at 26 weeks.174”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [174]
In the citing paper
“In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to −14.7% compared to −2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [25]
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“In a multicenter phase 2 trial, 272 participants (mean age, 54.2 years; mean BMI, 37.9 kg/m 2 ) were randomly assigned to 1 of 4 doses of oral orforglipron (12, 24, 36, or 45 mg) once daily or placebo, for 36 weeks (Wharton et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Self-citationDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Self-citationLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Cited by
Items 101–200 of 509
Treatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
Shamim, M. A., Patil, A., Amin, U., Roy, T., Tiwari, K., Husain, N., Kumar, J., Chenchula, S., Rao, P. P., Ganesh, V., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15777 · Cited by 26
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
Ke, Z., Ma, Q., Ye, X., Wang, Y., Jin, Y., Zhao, X., & Su, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116471 · Cited by 28
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice
Douros, J. D., Novikoff, A., DUBOIS, B. N., Rohlfs, R., Mokrosiński, J., Hogendorf, W. F. J., Augustin, R., Merkestein, M., Martini, L. B. E., Linderoth, L., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102124 · Cited by 25
“Orforglipron has shown significant effects to lower body weight in a phase 2 study of patients with obesity, driving weight loss comparable to that of full, unbiased peptide agonists like semaglutide [28].”
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis
Hu, Y., Yang, B., Xiao, C., Yang, X., Zhang, H., Yang, P., Du, X., Zhang, G., Liang, B., Bai, N., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.001 · Cited by 32
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“A recent clinical study showed that a small-molecule GLP-1R agonist led to highly significant weight loss, albeit with many of the same side effects of the peptide GLP-1R agonists ( 123 ).”
BackgroundThe GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines
Douros, J. D., Mokrosiński, J., & Finan, B. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0226 · Cited by 31
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Karam, L. B., Mabilleau, G., & Paccou, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07664-1 · Cited by 30
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“Across both trials, orforglipron produced significant, sustained weight reductions over 72 weeks, with the highest dose yielding mean body weight loss of 12–15% in non-diabetic participants and 10–12% in T2D populations [25,30,46,47].”
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 26
“Despite the approval of an oral formulation of semaglutide for treating T2D, the focus on developing small-molecule agonists and positive allosteric modulators of the GLP-1R has intensified 86,87 .”
Saldívar-Cerón, H. I., Vargas-Camacho, J. A., León‐Cabrera, S., Briseño-Díaz, P., Castañeda-Ramírez, A. E., Muciño-Galicia, A. E., & Díaz-Domínguez, M. R. (2025) · Scientia Pharmaceutica · doi:10.3390/scipharm93020026 · Cited by 25
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 22
“Orforglipron is a novel non-peptide small-molecule GLP-1 receptor agonist with notable weight loss results from phase 2 trials and a safety pro fi le similar to other incretin-based therapies [121].”
Glucagon-Like Peptide-1 Agonists: A Practical Overview for Plastic and Reconstructive Surgeons
Stanton, E. W., Manasyan, A., Banerjee, R., Hong, K. M., Koesters, E. C., & Daar, D. A. (2024) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000004089 · Cited by 23
The Impact and Safety of GLP‐1 Agents and Breast Cancer
Parsons, K., Montalvo, M., Fischbach, N. A., Taylor, M. A., Alfaro, S., & Lustberg, M. B. (2025) · Cancer Medicine · doi:10.1002/cam4.70932 · Cited by 24
“Orforglipron is a once-daily oral nonpeptide GLP-1 receptor agonist that is currently undergoing development to manage weight and treat T2DM [56].”
InfluentialSignaling architecture of the glucagon-like peptide-1 receptor
Austin, G. O., & Tomás, A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194752 · Cited by 23
“Novel small molecule GLP-1R agonists such as danuglipron (102) and orforglipron (103), with distinct engagement of GLP-1R transmembrane domains, also exhibit marked differences in their trafficking and spatiotemporal signaling phenotypes (54), raising the possibility of fine-tuning receptor…”
A brain reward circuit inhibited by next-generation weight-loss drugs in mice
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A., Li, O., Ogilvie, S., Keeler, A. B., Tian, G., Shi, Y., Koita, O., et al. (2026) · Nature · doi:10.1038/s41586-026-10444-4 · Cited by 23
“To validate the clinical relevance of these orally bioavailable small-molecule GLP1RAs, we confirmed that oral danuglipron significantly reduced blood glucose levels (Fig.”
InfluentialEmbracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)
Moyad, M. A. (2023) · Current Urology Reports · doi:10.1007/s11934-023-01180-7 · Cited by 21
“Oral orforglipron (− 15% weight loss) [94] and once-weekly subcutaneous retatrutide are two of the many examples [95].”
BackgroundPhan, J., Chang, P. W., Issa, D., Turner, R., Dodge, J. L., Westanmo, A. D., Karna, R., Olive, L., Bahdi, F., Aldzhyan, V., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002969 · Cited by 26
“Inaddition,newerGLP1-RAssuchas semaglutidemayhaverenal-protectivebene fi ts in patients with T2DM and new oral agents areon the horizon (6,7).”
The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review
Shen, M. R., Owusu-Boaitey, K. E., Holsen, L. M., & Suzuki, J. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001347 · Cited by 25
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
“[26] Other two oral GLP1RAs under development for the management of obesity and T2DM include Danuglipron [27] (selective small‑molecule GLP1RA) and Orforglipron [28] (non‑peptide GLP1RA molecule).”
Current and Future Medications for Obesity Treatment
Kushner, R. F., Jastreboff, A. M., & Ryan, D. H. (2025) · JAMA · doi:10.1001/jama.2025.13665 · Cited by 24
Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Suliman, M. H., Ahmed, E. O., Mohamed, A. N., Musa, H. H., Jalal, M., & Gasmallah, S. I. (2025) · Journal of Obesity · doi:10.1155/jobe/9919810 · Cited by 24
“In a pivotal phase 2 randomized trial published in the New England Journal of Medicine, orforglipron, a once-daily oral nonpeptide GLP-1RAs, demonstrated substantial and sustained weight loss among adults with obesity, with efcacy comparable to injectable agents and an acceptable safety profle [35].”
Chetty, A. K., Rafi, E., Bellini, N. J., Buchholz, N., & Isaacs, D. M. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.12.010 · Cited by 23
Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
“49 A meta-analysis of randomized controlled clinical trials of orforglipron for obese patients showed that the percentage of patients who had > 15% weight loss was greater with doses of 24, 36, or 45 mg/day.”
The role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 22
“79,80 In contrast to oral semaglutide, which has complex administration requirements with respect to food, water and other medications, and limited bioavailability (0.4%-1.0%), 81 orforglipron has no food or water restrictions and a bioavailability of 20%-40%.”
InfluentialPharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh, R. A. R. A., Hartmann, P., Olson, O., Gupta, O. T., Kumar, S., Ibrahim, S. H., Fawaz, R. L., Aqul, A. A., & Hassan, S. M. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12402 · Cited by 23
Khani, M., Afsahi, R., Nasab, A. E., Bi’aragh, S. H., Rasouli, K., Ahangar, M. H., Soltani, A., & Pourahmad, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01925-z · Cited by 23
Dozens of new obesity drugs are coming: these are the ones to watch
Dolgin, E. (2025) · Nature · doi:10.1038/d41586-025-00404-9 · Cited by 19
Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective
Sidik, S. (2023) · Nature · doi:10.1038/d41586-023-02092-9 · Cited by 18
Jeyakumar, Y., Richardson, L., Sarma, S., Retnakaran, R. R., & Kramer, C. K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-017177 · Cited by 21
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Sarzani, R., Landolfo, M., Pentima, C. D., Ortensi, B., Falcioni, P., Sabbatini, L., Massacesi, A., Rampino, I., Spannella, F., & Giulietti, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1365183 · Cited by 26
“In comparison, a weight reduction of at least 10% by week 36 was observed in up to 75% of patients at a dose of 45 mg in non-diabetic obese patients with related improvement in their cardiometabolic measures (131).”
BackgroundRecent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Velji-Ibrahim, J., Radadiya, D. K., Devani, K., Patel, H. K., Nathani, P., Hassan, C., Pugliese, N., Thompson, C., & Sharma, P. (2025) · Journal of Obesity · doi:10.1155/jobe/3897161 · Cited by 23
“For example, orforglipron, a once-daily, oral, nonpeptide GLP-1 RA, may provide a competitive alternative to oral semaglutide as it does not require fasting [47].”
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Obesity – Standards, trends and advances
Gołacki, J., & Matyjaszek‐Matuszek, B. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.04.001 · Cited by 17
Patoulias, D., Koufakis, T., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Pragmatic and Observational Research · doi:10.2147/por.s471476 · Cited by 19
“74 Other drugs, such as cagrilintide, a once-weekly, subcutaneously administered, amylin analogue, 75 or survodu-tide, a dual glucagon and GLP-1 receptor agonist, also administered once-weekly subcutaneously, 76 have recently been tested in Phase 2 RCTs for the treatment of adults with obesity…”
MethodMechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
“Furthermore, new molecules featuring innovative mechanisms [188 –190 ] ( Table 5 ) or improved pharmacokinetic and pharmacodynamic [155 , 191 ] could offer greater efficacy with similar AEs as compared to currently available WL medications.”
Advances in incretin-based therapeutics for obesity
ROSENKILDE, M. M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00938-w · Cited by 17
Zhang, M., Yue, X., Xu, S., Piao, J., Zhao, L., Shu, S., Kuzuya, M., Li, P., Hong, L., Kim, W., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202400158r · Cited by 18
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
le Roux, C. W., & Mondoh, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2311731 · Cited by 17
“…the first nonpeptide oral GLP-1 receptor agonist developed for obesity treatment, demonstrated significant efficacy in a phase 2 randomized double-blind trial among adults with obesity, leading to weight reduction of 14.7% (15.4 kg), in contrast to the placebo group’s 2.3% (2.4 kg) reduction [23].”
BackgroundInfluentialMoreno, Ó., Reyes‐García, R., Pardo, I. M., López-Martínez, M., & Soler, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae039 · Cited by 15
“…and obese individuals achieved WL between 7% and 17%, superimposable to semaglu-tide 2.4 mg [86 ,87 ], while orforglipron ( a chemically synthesized, non-peptide, partial, biased agonist of human GLP1R) achieved average WLs between 10% and 15% in the same populations in phase 2 studies [88 , 89 ].”
BackgroundInfluentialRecent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation
John, S., Bhowmick, K., Park, A., Huang, H., Yang, X., & Mishra, L. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00172-x · Cited by 15
“Other GLP-1 RA, such as Orforglip-ron (Wharton et al. 2023), Liraglutide (Pi-Sunyer et al. 2015), CagriSima (Frias et al. 2023), GIP/GLP-1/glucagon RA, such as Retatrutide (Jastreboff et al. 2023) also reduce body weight ~ 10-15%.”
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“In a Phase 2 clinical trial for overweight patients, orforglipron showed substantial efficacy, achieving a mean weight reduction of −9.4% to −14.7% at 36 weeks, compared with −2.3% with placebo [179].”
InfluentialG protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
“…with lower activation of the b -arrestin pathway (28), resulted in body weight reductions up to 12.6% (placebo adjusted) at 36 weeks in obese non-diabetic patients (29) while Danuglipron, a GLP-1R full agonist achieved approximately up to 4-5% body weight lowering at 16 weeks in T2D (30, 31).”
BackgroundInfluentialAntidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
Prentza, V., Pavlidis, G., Ikonomidis, I., Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Thymis, J., Palaiodimou, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195786 · Cited by 15
“Moreover, once-daily oral therapy with orforglipron, a nonpeptide GLP-1RA, was associated with weight reduction after 36 weeks of administration in adults with obesity [68].”
BackgroundForst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists
Feng, J., & Jin, T. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0026 · Cited by 16
“[76] Several clinical trials on additional GLP-1-based agents including triple agonists (Retatrutide), [77] oral formation (Orforglipron), [78] and combination therapy ( CagriSema) are in the late phase of trials.”
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Review on obesity management: diet, exercise and pharmacotherapy
Peri, K., & Eisenberg, M. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000246 · Cited by 13
Takrori, E., Peshin, S., & Singal, S. (2025) · Medicina · doi:10.3390/medicina61111987 · Cited by 13
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
D’Annibale, D. A., Mimoto, M. S., McCowen, K. C., & Malhotra, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001208 · Cited by 13
Central and peripheral neural circuits regulating glucose homeostasis
Espinoza, D., Seibold, F., & Stanley, S. A. (2025) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00036-8 · Cited by 17
“There has also been signi fi cant investment to create an oral alternative for GLP1R agonists with several therapies currently in development 189 and clinical trials 190 .”
Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus
Mszar, R., Katz, M. E., Grandhi, G. R., Osei, A. D., Gallo, A., & Blaha, M. J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01202-w · Cited by 17
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 14
Liu, L., Rashid, M., & Wess, J. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00867 · Cited by 16
Incretin-Based Therapies and Cancer: What’s New?
Medenica, S., Bogdanović, J. M., Vekić, J., Vojinović, T., Babić, I., Bogdanovic, L. M., Maggio, V., El‐Tanani, M., & Rizzo, M. (2025) · Medicina · doi:10.3390/medicina61040678 · Cited by 13
“Notably, its effects on pancreatic enzymes and calcitonin levels were consistent with those observed in other GLP-1RA classes [70–72].”
Guy, A., Azab, A. N., Liberty, I. F., Afawi, Z., Alhoashla, A., & Abu Tailakh, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15436 · Cited by 12
Grandhi, N., Liu, L., Wang, M., Thomas, T. S., Schoen, M. W., Sanfilippo, K. M., Gao, F., Colditz, G. A., Carson, K. R., Janakiram, M., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae095 · Cited by 13
“Recently, GLP-1 receptor agonists have gained widespread use because of their weight-loss effects (29-31).”
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
“An oral GLP-1 receptor agonist, orfoglipron, has demonstrated promising results in phase II trials for obesity, with weight loss ranging from 9.4% to 14.7% over 36 weeks, comparable to other injectable GLP-1 analogues (142).”
InfluentialObesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
“199 At 36 weeks, weight reductions ranged from −9.4% to −14.7%, compared to −2.3% in the placebo group.”
InfluentialStumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Gomaa, M. S., Alturki, M. S., Tawfeeq, N., Hussein, D. A., Pottoo, F. H., Khzem, A. H. A., Sarafroz, M., & Abubshait, S. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121607 · Cited by 14
Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
Dreher, L., Kylies, D., Danser, A. H. J., & Wenzel, U. O. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25112 · Cited by 13
Kim, A. R., Jeon, S.-G., Park, S., Hong, H., Kim, B. K., Kim, H., Hong, C., & Yang, B. (2025) · Microorganisms · doi:10.3390/microorganisms13061211 · Cited by 12
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Wang, Q., Wu, D., & Huang, Y. T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1682814 · Cited by 11
“Oral formulations show similar ef fi cacy but with higher incidence of gastrointestinal adverse events (94).”
Management of type 2 diabetes in the new era
Liakos, A., Karagiannis, T., Avgerinos, I., Malandris, K., Τσάπας, Α., & Bekiari, E. (2023) · HORMONES · doi:10.1007/s42000-023-00488-w · Cited by 13
“Finally. orforglipron is another nonpeptide GLP-1 receptor agonist for daily oral administration for which weight loss up to 14.7% among patients with obesity has been observed in a phase 2 clinical trial [31].”
BackgroundInfluentialHarrington, J., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Lingvay, I., Pagidipati, N. J., Sattar, N. A., Spall, H. G. C. V., Verma, S., & McGuire, D. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02016-z · Cited by 12
Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing
Ahn, Y. J., Maya, J., & Singhal, V. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00566-z · Cited by 12
“In another phase 2 trial, orforglipron, a new oral daily nonpep-tide GLP-1 receptor agonist, produced a − 14.7% weight loss effect compared to − 2.3% placebo at 36 weeks in adult participants [63].”
InfluentialCardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
Morissette, A., & Mulvihill, E. E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.012 · Cited by 13
Zhang, S., Yu, B., Xu, J., Jin, S., Li, Y., Bing, H., Li, J., Ma, X., Zhang, X., & Zhao, L. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0533 · Cited by 10
Self-citationLütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0469 · Cited by 10
“In contrast, orforglipron, lacking a peptide in its chemical formulation, does not require such precautions to enhance absorption and may be a potential alternative in obesity treatment (7,11,29).”
InfluentialDiscovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists
Chen, X., Xu, S., Yang, S. C., Yu, Z.-Z., Chen, Y., Wu, H., Bao, Q., You, Q., Guo, X., & Jiang, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02616 · Cited by 11
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
From pathophysiology to novel approaches for obesity-associated hypertension
Kanbay, M., Yayci, E., Genc, C., Çöpür, S., Aktaş, Ö. Y., Sarafidis, P. A., Covic, A. C., Ortíz, A., & Laffin, L. J. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf218 · Cited by 12
“However, no significant changes were observed in diastolic BP ( DBP) [73 ].”
Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations
Kim, D.-H., & Kim, J.-E. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00762-6 · Cited by 10
““AI and digital twin-based drug formulation optimization”) (Kawai et al. 2020 ; Griffith et al. 2022; Frias et al. 2023; Saxena et al. 2023; Wharton et al. 2023).”
Miramontes‐González, J. P., Rodrigo-Alaíz, Á., Gabella-Martín, M., Calle, D. G., Carretero-Gómez, J., & Corral-Gudino, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01829-1 · Cited by 11
“A prespeci‑ fied nephrology analysis showed a 22% relative risk reduction in the composite renal endpoint (new macro‑albuminuria, doubling of serum cre‑ atinine, dialysis, or renal death) driven mainly by a 26% fall in new‑onset macro‑albuminuria [8, 36].”
Zhang, Y., Zhang, C., gong, X., cheng, P., Fu, H., Diao, L., & Song, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-03933-9 · Cited by 13
“Three studies were treated with semaglutide (SME) [28–30], three with LIR [31–33], one with SME or LIR [34], one with oral semaglutide (OSM) [35], one with orforglipron (ORF) [36], two with tirzepatide (TZP) [37, 38] and one with retatrutide (RET) [39].”
Patil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
“Additionally, orforglipron, a novel small molecule non-peptide GLP-1RA may also be promising (Rosenstock et al., 2025; Wharton et al., 2025; Wharton et al., 2023) given its oral route of administration and similar effects in the brain to the injected peptide GLP-1RAs (Sloop et al., 2024).”
Johnson, A. J., O’Sullivan, E. N., Valyasevi, P., Metras, B. N., Jang, S., Shields‐Cutler, R. R., Arlinghaus, K. R., Harindhanavudhi, T., & Teigen, L. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0219 · Cited by 11
Singh, A., & Nissen, S. E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0122 · Cited by 11
“28 Tirzepatide, a Dual GLP-1 – GIP Receptor Agonist Tirzepatide is an acylated peptide engineered to stimulate receptors for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP).”
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“Daily 24 to 45 mg orforglipron doses positively promoted weight loss [123,124].”
Pandey, R. K., Jan, M., Mohammad, A., Jawaid, K. A., Naveed, M., Abid, M. A., Amir, A. B., Ahmed, S., Safiullah, M., Bhatti, M. I., et al. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70134 · Cited by 9
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Zhang, J., Wei, J., Lai, W., Sun, J., Bai, Y., Cao, H., Guo, J., & Su, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041651 · Cited by 9
“Orforglipron may provide a safe and effective once-daily oral treatment alternative to injectable GLP-1RAs or peptide oral formulations that are effective in improving blood sugar and significantly reducing body weight [44,45].”
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Goldman, S. N., Mani, K., Scharfenberger, T., Kleinbart, E. P., Hui, A. T., Ramos, R. D. L. G., Fourman, M. S., & Eleswarapu, A. S. (2025) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2025.100612 · Cited by 17
“GLP-1 RAs promote substantial weight loss, enhance glycemic control, and reduce the risk of myocardial infarction, stroke, and cardiovascular-related death in diverse patient groups, including those with type 1 and 2 DM and obese/overweight individuals [ 17–20 ].”
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 12
Sonne, N., Roque, M., Zachariassen, L. F., Porsgaard, T., Pors, S. E., Cavalera, M., Jones, C., Osborn, O., Thorbek, D. D., Riis, M. L., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106121 · Cited by 9
“17–24 Orforgli-pron is the first small-molecule GLP1R agonists to successfully complete a phase 3 trial for type 2 diabetes 24 and is now advancing into multiple phase 3 trials for both type 2 diabetes and obesity.”
Kowalska, M. K., El‐Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041886 · Cited by 10
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
“The safety profile of orforglipron was consistent with that of the GLP-1 RAs class [71].”
InfluentialKelkar, R., Barve, N., Kelkar, R., Kharel, S., Khanapurkar, S., & Yadav, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1453297 · Cited by 10
Metadata
- Authors
- Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., & Konig, M.
- Affiliations
- Eli Lilly (United States) (US)
- From McMaster University, York University, and Wharton Weight Management Clinic — all in Toronto (S.W.); Texas Diabetes and Endocrinology, Austin (T.B.), and Velocity Clinical Research at Medical City, Dallas (J.R.) — both in Texas; Alliance for Multispecialty Research, Norman, OK (L.C.); and Eli Lilly, Indianapolis (S.R., R.L., X.M., K.J.M., A.H., D.R., E.P., C.K., M.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-07
- Volume
- 389
- Issue
- 10
- Pages
- 877-888
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4381716537
- Semantic Scholar
- db8284957df7f480bc8b5957f73388bfd42590cf
- Cited by
- 478
- References
- 19
- Citations by year
- 2026: 125 · 2025: 175 · 2024: 133 · 2023: 45
- FWCI
- 74.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- orforglipron, GLP-1 receptor agonists, obesity, weight loss, cardiometabolic risk, gastrointestinal adverse effects, dose escalation, overweight adults, weight change, drug safety and efficacy, weight-related comorbidities, dose-response relationship, dose-limiting adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.